Page 288 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
References
1. Piris MA, Isaacson PG, Swerdlow SH, et al Splenic marginal zone lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC Press; 2017. p. 223-225.
2. Arcaini L, Rossi D, Paulli M. Splenic marginal zone lymphoma: from genetics to management. Blood. 2016;127(17):2072-2081.
3. Kalashnikov I, Tanskanen T, Viisanen L, et al. Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study. Blood Cancer J. 2023:13(62):1-8.
4. Luminari S, Merli M, Rattotti S, et al. Brief report early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 Study. Blood. 2019;134(10):798-801.
5. Zucca E, Arcaini L, Buske C, et al. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(1):17-29.
6. Kalpadakis C, Pangalis GA, Sachanas S, et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood. 2018;132(6):666-670.
7. Lyu R, Wang T, Wang Y, et al. Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma. Br J Haematol. 2021;194(5):862-869.
8. Cervetti G, Galimberti S, Pelosini M, Ghio F, Cecconi N, Petrini M. Significant efficacy of 2-chlorodeoxyadenosine and rituximab
in the treatment of splenic marginal zone lymphoma (SMZL):
extended follow-up. Ann Oncol. 2013;24(9):2434-2438.
9. Iannitto E, Bellei M, Amorim S, et al. Efficacy of bendamustine
and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol. 2018;183(5):755-765.
10. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia. 2008;22(3):487-495.
11. Drandi D, Alcantara M, Benmaad I, et al. Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL Network. Hemasphere. 2020;4(2):e347.
12. Bommier C, Lambert J, Nowakowski G, Zucca E, Thieblemont C. What prognostic markers should be evaluated in marginal zone lymphoma? A survey among leading international experts. Hemasphere. 2022;6(2):e680.
13. Else M,Marín-Niebla A, de la Cruz F, et al. Rituximab, when used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol. 2012;159(3):322-328.
14. Albano D, Giubbini R, Bertagna F. 18F-FDG PET/CT in splenic marginal zone lymphoma. Abdom Radiol. 2018;43(10):2721-2727.
15. Iannitto E, Minardi V, Callea V, et al. Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma. Eur J Haematol. 2006;76(2):134-140.
Haematologica | 109 July 2024
2302